Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaws (MRONJ)–formerly referred to as bisphosphonate-related osteonecrosis of the jaws …

Since the initial description of medication‐related osteonecrosis of the jaw (MRONJ) almost
two decades ago, the potential pathophysiology and risk factors have been elaborated on in …

Aims Cardiotoxicity by doxorubicin predicts worse prognosis of patients. Accumulation of
damaged DNA has been implicated in doxorubicin-induced cardiotoxicity. SIRT1, an NAD+ …

Long-term usage of bisphosphonates, especially zoledronic acid (ZA), induces
osteogenesis disorders and medication-related osteonecrosis of the jaw (MRONJ) in …

Aim Previous studies have shown that silent information regulator 1 (SIRT1) expression is
elevated in rheumatoid arthritis (RA) patients. However, whether gene polymorphisms in …

Medication‐related osteonecrosis of the jaw (MRONJ) is a rare but serious drug‐related
adverse event. To identify pharmacogenomic markers of MRONJ associated with …

Haplotyping or determination of genetic phase has always played a pivotal role in MHC
(HLA studies) both in helping to understand inheritance patterns in diseases such as type 1 …

Osteonecrosis of the jaw (ONJ) is a severe clinical condition characterized mostly but not
exclusively by an area of exposed bone in the mandible and/or maxilla that typically does …

Medication‐related osteonecrosis of the jaw (MRONJ) is a severe complication of
antiresorptive or antiangiogenic medications, used in the treatment of bone malignancy or …

Background/purpose Local infection is a risk factor for medication-related osteonecrosis of
the jaw (MRONJ), along with invasive dental treatment of the bone; the tooth that is the …